Cempra Pharmaceuticals, Inc. Presents Late-Breaker On Solithromycin's Anti NASH Effects In An Animal Model At DDW 2014
5/6/2014 10:03:11 AM
CHAPEL HILL, N.C., May 6, 2014 (GLOBE NEWSWIRE) -- Cempra, Inc., (Nasdaq:CEMP) today announced a late-breaker presentation demonstrating that solithromycin significantly reduced ballooning degeneration and inflammation which are histological signs of non-alcoholic steatohepatitis (NASH) in an animal model at Digestive Disease Week (DDW) in Chicago. The abstract titled, "Anti-NASH Effects of Solithromycin in NASH-HCC Mouse Model," will be presented at 9:15 a.m. CDT, Tuesday, May 6, in Room S015A at McCormick Place in Chicago.
Help employers find you! Check out all the jobs and post your resume.
comments powered by